Nycomed, a pharmaceutical company based in Zurich, Switzerland, was acquired by Takeda Pharmaceutical Co. in 2011. Takeda’s motive for acquiring Nycomed was multifold. Some of Nycomed’s products and pipeline were within segments hitherto not covered by Takeda, and would therefore constitute an enrichment of the Takeda product portfolio. Nycomed was well established in regions were Takeda’s presence was weak, especially Europe including Russia. Furthermore, the acquisition of Nycomed would mean a boost to Takeda’s evolution toward attaining an internationalized corporate culture.